Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...

GILD’s outperformance becomes more evident ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

In the latest market close, Gilead Sciences (GILD ... and the technology-dominated Nasdaq saw a decrease of 2.64%. The HIV and hepatitis C drugmaker's shares have seen an increase of 17.6% ...

Let's take a look at what these Wall Street heavyweights have to say about Gilead Sciences (GILD) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

FOSTER CITY, Calif., February 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Earnings Yield Investor model based on the published ...

Gilead Sciences, Inc. GILD announced that the European Medicines Agency (“EMA”) has validated the company’s marketing authorization application and EU-Medicines for all applications for its ...

GILD is currently trading at $111.43 up 1.35 percent or $1.48 on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those ...